Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study

Lieke Tweehuysen*, Victor J. B. Huiskes, Bart J. F. van den Bemt, Johanna E. Vriezekolk, Steven Teerenstra, Frank H. J. van den Hoogen, Cornelia H. van den Ende, Alfons A. den Broeder

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1408-1418
Number of pages11
JournalArthritis & Rheumatology
Volume70
Issue number9
DOIs
Publication statusPublished - 1 Sep 2018

Keywords

  • NATIONWIDE NONMEDICAL SWITCH
  • RHEUMATOID-ARTHRITIS
  • DISEASE-ACTIVITY
  • SELF-EFFICACY
  • INFLAMMATORY ARTHRITIS
  • CLINICAL-OUTCOMES
  • DANBIO REGISTRY
  • INFLIXIMAB
  • EXPERIENCE
  • CT-P13

Cite this